

# Down-regulation of *TSGA10*, *AURKC*, *OIP5* and *AKAP4* genes by *Lactobacillus rhamnosus* GG and *Lactobacillus crispatus* SJ-3C-US supernatants in HeLa cell line

Supernatanty *Lactobacillus rhamnosus* GG a *Lactobacillus crispatus* SJ-3C-US snižují expresi genů *TSGA10*, *AURKC*, *OIP5* a *AKAP4* v HeLa buňkách

Nouri Z.<sup>1</sup>, Neyazi N.<sup>1</sup>, Modarressi MH.<sup>2</sup>, Karami F.<sup>3</sup>, Abedin-Do A.<sup>4</sup>, Taherian-Esfahani Z.<sup>4</sup>, Ghafouri-Fard S.<sup>4</sup>, Motevaseli E.<sup>5</sup>

<sup>1</sup> Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

<sup>3</sup> Department of Medical Genetics, Science and Research Branch, Islamic Azad University, Tehran, Iran

<sup>4</sup> Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>5</sup> Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

## Summary

**Background:** Cancer testis antigens (CTAs) are considered cancer biomarkers due to their highly specific expression pattern in human malignancies and near absence from normal somatic tissues. Their specific expression has made them potential targets for early diagnosis, assessment of patients' prognosis and treatment of cancer in recent years. *Lactobacilli* are a group of probiotics with anti-cancer, immunomodulatory and other beneficial features. These bacteria have been shown to alter expression of several cancer-related genes. **Aim:** We investigated the effect of *Lactobacillus rhamnosus* GG supernatant (LRS) and *Lactobacillus crispatus* SJ-3C-US supernatant (LCS) on expression of four CTAs (*TSGA10*, *AURKC*, *OIP5* and *AKAP4*) in HeLa cell line after synchronization using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay and quantitative real-time polymerase chain reaction. **Results:** LRS and LCS inhibited HeLa cell growth after 24 h as demonstrated by MTT assay. Expressions of all CTAs were down-regulated after treatment with both supernatants. **Conclusion:** This study showed the role of *Lactobacilli* in down-regulation of CTAs genes. Such expression change might be involved in the anticancer effects of these *Lactobacilli*. The underlying mechanisms of these observations are not clear but epigenetic modulatory mechanisms may participate in this process. Future studies are needed to assess functional roles of *Lactobacilli* in modulation of other cancer-related genes.

## Key words

probiotic – cancer testis antigen – biomarker – HeLa cell line

This study was financially supported by Research Deputy of Tehran University of Medical Sciences. The authors are thankful of Genetic and Biotechnology lab staffs for their cooperation in this research.

Tato studie byla podpořena Teheránskou univerzitou lékařských věd. Autoři děkují členům Genetické a biotechnologické laboratoře za pomoc při výzkumu.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zaslané do biomedicínských časopisů.



Soudeh Ghafouri-Fard, MD, PhD  
Department of Medical Genetics  
Shahid Beheshti University  
of Medical Sciences  
Bldg No. 2 SBUMS  
Arabi Ave, Daneshjoo Blvd, Velenjak  
Tehran, Iran  
e-mail: s.ghafourifard@sbmu.ac.ir



Elahe Motevaseli, MD, PhD  
Department of Molecular Medicine  
School of Advanced Technologies in  
Medicine  
Tehran University of Medical  
Sciences  
Keshavarz Blv. Vali-e Asr Ave.  
Tehran, Iran  
e-mail: e\_motevaseli@tums.ac.ir

Submitted/Obdrženo: 19. 8. 2018

Accepted/Přijato: 30. 9. 2018

doi: 10.14735/amko2018429

## Souhrn

**Východiska:** Nádorové antigeny testis (CTA) jsou považovány za nádorové biomarkery z důvodu jejich vysoce specifické exprese u lidských malignit a jelikož se téměř nevyskytují v normálních somatických tkáních. Díky své specifické expresi umožňují v posledních letech lépe stanovit včasnou diagnózu, prognózu pacientů a léčbu rakoviny. Lactobacily jsou skupina probiotik s protinádorovými, imunomodulačními a dalšími prospěšnými vlastnostmi. Bylo prokázáno, že tyto bakterie mění expresi několika genů souvisejících s nádory. **Cíl:** Po synchronizaci buněk HeLa pomocí MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-difenylnitrotetrazoliumbromid] jsme pomocí kvantitativní polymerázové řetězové reakci v reálném čase zkoumali vliv supernatantu *Lactobacillus rhamnosus* GG (LRS) a supernatantu *Lactobacillus crispatus* SJ-3C-US (LCS) na expresi čtyř CTA (*TSGA10*, *AURKC*, *OIP5* a *AKAP4*). **Výsledky:** LRS a LCS inhibovaly růst buněk HeLa po 24 hod, což bylo prokázáno pomocí MTT testu. Expresie všech CTA byly po léčbě oběma supernatanty nižší. **Závěr:** Tato studie prokázala úlohu laktobacilů při snížení exprese genů CTA. Taková změna exprese může být zapojena do protinádorových účinků těchto laktobacilů. Základní mechanismy těchto pozorování nejsou jasné, ale v tomto procesu se mohou účastnit epigenetické modulační mechanismy. K posouzení funkčních rolí laktobacilů v modulaci jiných genů souvisejících s nádory je třeba dalších studií.

## Klíčová slova

probiotika – nádorové antigeny testis – biomarker – HeLa buněčná linie

## Background

Cancer testis antigens (CTAs) are broadly expressed in various cancer tissues and cancer cell lines, but not in normal tissues except for germ cells. This highly specific expression suggests CTAs play a role in carcinogenesis [1,2]. As they trigger immune response, they are considered targeted immunotherapy options for many cancers, including cervical and ovarian cancers [3,4]. Moreover, their cancer-specific pattern has made them diagnostic, prognostic and therapeutic biomarkers [5,6]. CTAs expression appears to be regulated through epigenetic mechanisms, such as deoxyribonucleic acid (DNA) methylation. Demethylation of promoter CpG islands in their coding genes has been associated with their expression in a range of solid tumors [7]. *Lactobacilli* are a group of probiotics whose sufficient administration has beneficial effects on host health [8]. They are also normal flora of vagina which protect genitourinary tract from microbial infections [9]. In addition to anti-tumoral effects, they modulate immunogenic responses, regulate cytokines production and alter expression of tumor biomarkers [10–12]. *Lactobacillus rhamnosus* GG (*L. rhamnosus* GG) and *Lactobacillus crispatus* SJ-3C-US (*L. crispatus* SJ-3C-US) are two most predominant species of vagina and cervix which adhere to cervicovaginal cells [13,14]. Our previous study demonstrated the effect of *Lactobacilli* on modulation of CTAs expression in breast cancer cell line [15]. In the current

study, we aimed at assessment of their effect on expression of four CTAs (Testis specific 10 (*TSGA10*), Aurora kinase C (*AURKC*), Opa interacting protein 5 (*OIP5*) and A-Kinase anchoring protein 4 (*AKAP4*)) in HeLa cervical cancer cell line.

*TSGA10* has been primarily identified as CTAs by differential messenger ribonucleic acid (mRNA) display. Over-expression of *TSGA10* was observed in many cancer cell lines compared to normal tissue. *TSGA10* has been suggested as a target for immunotherapy in malignancies [16,17]. *AURKC* is a member of Aurora kinase family, which regulates different processes during cell division. *AURKC* is over-expressed in cervical and colorectal cancers and also in a wide range of cancer cell lines. Over-expression of *AURKC* can cause higher cell proliferation and migration through kinase activity [18]. *OIP5* is another CTAs gene, which is over-expressed in many types of cancer. *OIP5* is a putative binding partner of lamina-associated polypeptide 2α (LAP2α) which participates in cell cycle regulation and chromatin organization. *OIP5* knockdown has inhibited cell growth [19,20]. *AKAP4* transcription has been only detected during spermatogenesis. Moreover, most proteins in fibrous sheath of sperm flagellum are encoded by this gene. In fact, it is a scaffold protein which is needed for effective sperm motility [21]. It has been recognized as a CTA in a variety of cancers, including breast, colorectal and cervical cancers [22–24].

## Materials and Methods

### Cell culture

Human cervical cancer (HeLa) cell line was purchased from National Cell Bank of Iran, Pasteur Institute of Iran. Cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, California, USA) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, California, USA). Cells were kept under condition of 37 °C in humidified atmosphere of 5% CO<sub>2</sub> to allow adherence.

### Cell synchronization

HeLa cells were cultured in RPMI medium containing 10% FBS, and 1% penicillin/streptomycin for 24 h. Next, cells were counted and sub-cultured with equal numbers in four 25 ccm flasks and synchronized.

### Bacterial supernatant preparation

*L. rhamnosus* and *L. crispatus* bacteria were inoculated in de Man, Rogosa and Sharpe (MRS) broth (Merck; pH 6.5) and incubated for 24 h in 37 °C. Overnight culture of these two *Lactobacilli* contained 108 CFU (colony-forming unit)/mL. These cultures were centrifuged at 7,000 rpm for 7 min, and supernatant was isolated. *Lactobacillus rhamnosus* GG supernatant (LRS) and *Lactobacillus crispatus* SJ-3C-US supernatant (LCS) were filtered using 0.2 μm to remove any possible bacteria or debris. The pH of the LRS and LCS were reduced from 6.5 (MRS broth pH) to 4.3. A lactic acid control of MRS

with similar pH of both *Lactobacillus* supernatants (LS) was used to clarify whether cytotoxic effects are related to acidic pH or compounds existing in the supernatant. The following conditions were tested – LCS, pH 4.3; LRS, pH 4.3; MRS, pH 6.5; MRS adjusted with lactate (MRL, pH 4.3).

#### MTT assay

MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Sigma, St. Louis, Missouri) was performed to assess the inhibitory effects of LRS and LCS on HeLa cells. In total, 104 cells were seeded in 96-well plate and after 24 h incubation cells were treated with different concentrations (5, 10, 15, 20, 25%) of LS in triplicates. Cells were incubated for 24 h under condition of 37 °C and 5% CO<sub>2</sub>. Medium was aspirated out, 0.5 mg/mL MTT reagent was added and plates were kept in dark condition for 4 h. When MTT formazan crystals were produced, 100 µl of dimethyl sulfoxide was added and cell viability was measured by Elisa Plate Reader using the following formula:


$$\text{Viability (percentage of control)} = \frac{[(\text{absorbance sample} - \text{absorbance blank}) / (\text{absorbance control} - \text{absorbance blank})] \times 100}{100}$$

#### RNA extraction, cDNA synthesis and qRT-PCR

Total ribonucleic acid (RNA) was isolated from cultured cells (treated and untreated cells) using TriPure Reagent kit (Roche Applied Science, Germany). RNA quality and quantity were assessed using Nanodrop 2000c spectrophotometer (Thermo Scientific). Complementary DNA (cDNA) was synthesized using PrimeScript RT reagent kit (Takara Bio, Ohtsu, Japan). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze mRNA expression of target genes. Alteration in gene expression patterns of four CTAs (*TSGA10*, *AURKC*, *OIP5* and *AKAP4*) was assessed by rotor gene 3,000 corbette detection system. PCR was done in final volume of 10 µl containing 0.5 µl cDNA, 0.5 µl of forward and reverse primers (10 pmol), 5 µl 2× master mix (Takara Bio, Ohtsu, Japan), and 3.5 µl nuclease free water.

Tab. 1. The nucleotide sequences of primers.

Genes	Primer sequences	Product size (bp)	References
<i>TSGA10</i>	F: CAACGGCACATGCTATTCTCC R: CCACAGTGCTTATGGTTTCCTTC	252	15
<i>AURKC</i>	F: CGCCTCACAGTCGATGACTTT R: GCAGGATATTGGGGTGTGTAG	205	1
<i>OIP5</i>	F: GCCCTTCCTAGTTGGCATTGA R: GCAGCATGGGTAGAATACAGATG	111	1
<i>AKAP4</i>	F: GGCAGTCAAGGCTGTAGGAG R: GCTGTCCTTCTGGGTTGTAGAG	221	15
<i>PGM1</i>	F: AGCATTCCGATTTCCAGCAG R: GCCAGTTGGGGTCTCATACAAA	120	12
<i>HPRT1</i>	F: CCTGGCGTCGTGATTAGTGAT R: AGACGTTCAAGTCTGTCCATAA	131	1




Graph 1. Cytotoxic effects of different concentrations of LCS, LRS, MRL and MRS with on HeLa cell line as measured by MTT assay. The mean values of 3 separate experiments are shown in each point.

LCS – *Lactobacillus crispatus* SJ-3C-US supernatant, LRS – *Lactobacillus rhamnosus* GG supernatant, MRS – Man, Rogosa and Sharpe, HeLa – human cervical cancer cell line, MRL – MRS adjusted with lactate, MTT – [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], v/v – volume/volume

Primer sequences were obtained from previous studies [1,12,15] and verified using online Primer 3 software and The National Center for Biotechnology Information (NCBI) and The Basic Local Alignment Search Tool (BLAST). The thermal cycling condition was initiated with DNA denaturation at 95 °C for

10 s, following 50 cycles of 2 step denaturation at 95 °C for 10 s and annealing/extension at 65 °C for 30 s. For each condition, experiment was done in duplicate. Phosphoglucosyltransferase 1 (PGM1) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) genes were used as reference genes. Melting curve



**Graph 2. Expression levels of all CTAs were significantly decreased following treatment of HeLa cells with LCS and LRS. Asterisks show significance.**

CTAs – cancer testis antigens, HeLa – human cervical cancer cell line, LCS – *Lactobacillus crispatus* SJ-3C-US supernatant, LRS – *Lactobacillus rhamnosus* GG supernatant, MRS – Man, Rogosa and Sharpe, MRL – MRS adjusted with lactate

analysis was performed to confirm specificity of products. The nucleotide sequences of primers and amplicon sizes are shown in Tab. 1.

#### Statistical analysis

The half maximal inhibitory concentrations (IC50) of treatment strategies were compared using the Mann-Whitney test. Data were described as a mean  $\pm$  SE of 3 distinct experiments. Expression of CTAs were compared between treated and control cells expression using relative expression software tool (REST).

#### Results

##### The effects of LRS and LCS on HeLa cells

The results of cell growth inhibition based on MTT assay have shown that LRS and LCS have IC50 of 16% and 12% (v/v), respectively. Cytotoxic effects of both LRS on HeLa cells were meaningfully greater than MRS and MRL. The results of MTT assay are shown in Graph 1.

##### Down-regulation of CTAs by LCS and LRS

Expressions of CTAs were evaluated in HeLa cells after synchronization and treatment with supernatant of *Lactobacilli*. Supernatant of these two *Lactobacilli* significantly down-regulated transcripts of all CTA genes in HeLa cell line (Graph 2).

#### Discussion

CTA genes characteristics such as cancer-restricted expression profile, immunogenicity, association with tumor progression and induction of their expression by hypomethylation and/or histone acetylation have suggested their potential as cancer biomarker and therapeutic targets [25]. On the other hand, probiotics possess many anti-tumoral effects, such as anti-proliferative properties, mutagens eliminating effects, moderating side effects of chemotherapy, promoting survival and delaying tumor onset [26]. They also

inhibit tumor growth by stimulation of host anti-tumor immune responses [27].

Immunotherapeutic response of *L. rhamnosus* GG (live or lyophilized) has been observed in female C57BL/6 mice implanted with MB49 bladder cancer cells. Such effects have been mainly exerted through recruitment of neutrophils and macrophages in the tumor site [28]. The effects of *Lactobacilli* depend on preparation method and the administered dose. For example, *L. rhamnosus* GG (lived and heat-killed) can reduce production of TNF $\alpha$ -induced interleukin-8 (IL-8) through the NF $\kappa$ B/I $\kappa$ B pathway. While high dose ( $10^{10}$  CFU/L) of live *L. rhamnosus* GG increases IL-8 production, heat-killed *Lactobacilli* does not. Moreover, doses between  $10^8$  and  $10^6$  CFU/L of both preparations diminished TNF $\alpha$ -induced IL-8 production [29].

*L. rhamnosus* has anti-proliferative effects on ME-180 cell line (a human cervical epithelial-like adenocarcinoma cell line) via moderating cell cycle progression. Treatment with this *Lactobacilli* resulted in accumulation of host cells in G1 phase through enhancement of expression and nuclear accumulation of p21 [30]. Anti-proliferative effect of *L. crispatus* SJ-3C-US has been reported in MDA-MB-231 cell line, which has been accompanied by down-regulation of *ODF4*, *PIWIL2*, *RHOXF2*, and *TSGA10* [15]. In our previous study, we showed that *L. crispatus* and *L. rhamnosus* exist in cervix of healthy women and have cytotoxic effects on cervical cancer cells [9]. In this study, we reported the effect of these strains on expression of four CTAs gene. *TSGA10* expression has been previously detected in testes and malignant tissues. This gene encodes a protein of fibrous sheath that is a major constituent of sperm tail in mouse mature spermatozoa [17,31]. We previously reported down-regulation of *TSGA10* by *Lactobacillus acidophilus* and *L. crispatus* culture supernatants in MDA-MB-231 cells [15]. We hypothesize that its down-regulation by *Lactobacilli* might affect tumor cell mobility in HeLa or MDA-MB-231 cells. Future studies are needed to assess such effects in cancer cells.

*AURKC* is a regulatory serine/threonine kinase, which is involved in mitotic cell division, cytokinesis and meiosis. Abnormal cell division has been seen as a result of *AURKC* over-expression *in vitro* [32]. Down-regulation of *AURKC* can enhance the chemotherapeutic effects of some drugs [33]. Thus, observed down-regulation of *AURKC* by *Lactobacilli* might have clinical implications. Future studies are needed to assess whether *AURKC* suppression by *Lactobacilli* influences mitotic cell division in cancer cells.

*OIP5* accumulation occurs at telophase-G1 centromere and is necessary for formation and structure of centromeres/kinetochores. Knockdown of *OIP5* expression in gastric and colorectal cell line increased cell apoptosis [18]. *OIP5* also modulates growth and metastasis of hepatocellular malignant cells through AKT/mTORC1 and  $\beta$ -catenin signaling pathways. MiR-15b-5p inhibits these pathways in hepatocellular carcinoma by targeting *OIP5* [34]. The observed down-regulation of *OIP5* following treatment with *Lactobacilli* might affect cell growth and apoptosis which should be assessed in future studies.

*AKAP4* gene and protein expressions have been detected in 86% of cervical cancer cell lines where its silencing has led to inhibition of cell proliferation, migration, invasion and colony-forming capacity [24]. Its expression in different malignant tumors potentiated it as a target for cancer immunotherapy [35–37]. The present study demonstrated the negative effects of LRS and LCS on transcriptional activity of *AKAP4* in HeLa cells. Future investigations are needed to elaborate the detailed mechanism of probiotics action on invasive and proliferative characteristics of cervical cancer.

Herein, it was demonstrated that LRS and LCS treatment led to down-regulation of four CTAs in HeLa cells. The underlying mechanisms of these observations are not clear but epigenetic modulatory mechanisms may participate in this process.

## References

1. Yazarloo F, Shirkoobi R, Mobasheri MB et al. Expression analysis of four testis-specific genes *AURKC*, *OIP5*,

*PIWIL2* and *TAF7L* in acute myeloid leukemia: a gender-dependent expression pattern. *Med Oncol* 2013; 30(1): 368. doi: 10.1007/s12032-012-0368-8.

2. Por E, Byun HJ, Lee EJ et al. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1 and E2F-dependent manner. *J Biol Chem* 2010; 285(19): 14475–14485. doi: 10.1074/jbc.M109.084400.

3. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. *Arch Iran Med* 2009; 12(4): 395–404.

4. Cheng YH, Wong EW, Cheng CY. Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. *Spermatogenesis* 2011; 1(3): 209–220. doi: 10.4161/spmg.1.3.17990.

5. Sammut SJ, Feichtinger J, Stuart N et al. A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets. *Oncoscience* 2014; 1(5): 349–359.

6. Kulkarni P, Uversky VN. Cancer/testis antigens: “smart” biomarkers for diagnosis and prognosis of prostate and other cancers. *Int J Mol Sci* 2017; 18(4): e740. doi: 10.3390/ijms18040740.

7. Linnekamp JF, Butter R, Spijker R et al. Clinical and biological effects of demethylating agents on solid tumours – a systematic review. *Cancer Treat Rev* 2017; 54: 10–23. doi: 10.1016/j.ctrv.2017.01.004.

8. Begum PS, Madhavi G, Rajagopal S et al. Probiotics as functional foods: potential effects on human health and its impact on neurological diseases. *Int J Nutr Pharmacol Neurol Dis* 2017; 7(2): 23–33.

9. Motevaseli E, Shirzad M, Raoofian R et al. Differences in vaginal *Lactobacilli* composition of Iranian healthy and bacterial vaginosis infected women: a comparative analysis of their cytotoxic effects with commercial vaginal probiotics. *Iranian Red Crescent Med J* 2013; 15(3): 199–206. doi: 10.5812/ircmj.3533.

10. Abedin-Do A, Taherian-Esfahani Z, Ghafouri-Fard S et al. Immunomodulatory effects of *Lactobacillus* strains: emphasis on their effects on cancer cells. *Immunotherapy* 2015; 7(12): 1307–1329. doi: 10.2217/imt.15.92.

11. Eslami S, Hadjati J, Motevaseli E et al. *Lactobacillus crispatus* strain SJ-3C-US induces human dendritic cells (DCs) maturation and confers an anti-inflammatory phenotype to DCs. *APMIS* 2016; 124(8): 697–710. doi: 10.1111/apm.12556.

12. Nouri Z, Karami F, Neyazi N et al. Dual anti-metastatic and anti-proliferative activity assessment of two probiotics on HeLa and HT-29 cell lines. *Cell J* 2016; 18(2): 127–134.

13. Motevaseli E, Shirzad M, Akrami SM et al. Normal and tumour cervical cells respond differently to vaginal *Lactobacilli*, independent of pH and lactate. *J Med Microbiol* 2013; 62(Pt7): 1065–1072. doi: 10.1099/jmm.0.057521-0.

14. Kwok L, Stapleton AE, Stamm WE et al. Adherence of *Lactobacillus crispatus* to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection. *J Urol* 2006; 176(5): 2050–2054. doi: 10.1016/j.juro.2006.07.014.

15. Azam R, Ghafouri-Fard S, Tabrizi M et al. *Lactobacillus acidophilus* and *Lactobacillus crispatus* culture supernatants downregulate expression of cancer-testis genes in the MDA-MB-231 cell line. *Asian Pac J Cancer Prev* 2014; 15(10): 4255–4259.

16. Modarressi MH, Cameron J et al. Identification and characterisation of a novel gene, *TSGA10*, expressed in testis. *Gene* 2001; 262(1–2): 249–255.

17. Tanaka R, Ono T, Sato S et al. Over-expression of the testis-specific gene *TSGA10* in cancers and its immunogenicity. *Microbiol Immunol* 2004; 48(4): 339–345.

18. Tsou JH, Chang KC, Chang-Liao PY et al. Aberrantly expressed *AURKC* enhances the transformation and tumorigenicity of epithelial cells. *J Pathol* 2011; 225(2): 243–254. doi: 10.1002/path.2934.

19. Chun HK, Chung KS, Kim HC et al. *OIP5* is a highly expressed potential therapeutic target for colorectal and gastric cancers. *BMB Rep* 2010; 43(5): 349–354.

20. Koinuma J, Akiyama H, Fujita M et al. Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. *Cancer Sci* 2012; 103(3): 577–586. doi: 10.1111/j.1349-7006.2011.02167.x.

21. Inaba K. Sperm flagella: comparative and phylogenetic perspectives of protein components. *Mol Hum Reprod* 2011; 17(8): 524–538. doi: 10.1093/molehr/gar034.

22. Saini S, Jagadish N, Gupta A et al. A novel cancer testis antigen, A-kinase anchor protein 4 (*AKAP4*) is a potential biomarker for breast cancer. *PLoS One* 2013; 8(2): e57095. doi: 10.1371/journal.pone.0057095.

23. Jagadish N, Parashar D, Gupta N et al. A-kinase anchor protein 4 (*AKAP4*) a promising therapeutic target of colorectal cancer. *J Exp Clin Cancer Res* 2015; 34: 142. doi: 10.1186/s13046-015-0258-y.

24. Saini S, Agarwal S, Sinha A et al. Gene silencing of A-kinase anchor protein 4 inhibits cervical cancer growth *in vitro* and *in vivo*. *Cancer Gene Ther* 2013 Jul; 20(7): 413–420. doi: 10.1038/cgt.2013.32.

25. Scanlan MJ, Gure AO, Jungbluth AA et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. *Immunol Rev* 2002 Oct; 188: 22–32.

26. Patel S, Goyal A. Evolving roles of probiotics in cancer prophylaxis and therapy. *Probiotics Antimicrob Proteins* 2013; 5(1): 59–67. doi: 10.1007/s12602-012-9124-9.

27. Hu J, Wang C, Ye L et al. Anti-tumour immune effect of oral administration of *Lactobacillus plantarum* to CT26 tumour-bearing mice. *J Biosci* 2015; 40(2): 269–279.

28. Seow SW, Cai S, Rahmat JN et al. *Lactobacillus rhamnosus* GG induces tumor regression in mice bearing orthotopic bladder tumors. *Cancer Sci* 2010; 101(3): 751–758. doi: 10.1111/j.1349-7006.2009.01426.x.

29. Zhang L, Li N, Caicedo R et al. Live and dead *Lactobacillus rhamnosus* GG decrease tumor necrosis factor- $\alpha$ -induced interleukin-8 production in cocaco-2 cells. *J Nutr* 2005; 135(7): 1752–1756. doi: 10.1093/jn/135.7.1752.

30. Vielfort K, Weyler L, Söderholm N et al. *Lactobacillus* decelerates cervical epithelial cell cycle progression. *PLoS One* 2013; 8(5): e63592. doi: 10.1371/journal.pone.0063592.

31. Dianatpour M, Mehdipour P, Nayernia K et al. Expression of testis specific genes *TSGA10*, *TEX101* and *ODF3* in breast cancer. *Iran Red Crescent Med J* 2012; 14(11): 722–726. doi: 10.5812/ircmj.3611.

32. Dieterich K, Soto Rifo R, Faure AK et al. Homozygous mutation of *AURKC* yields large-headed polyloid spermatozoa and causes male infertility. *Nat Genet* 2007; 39(5): 661–665. doi: 10.1038/ng2027.

33. Tang A, Gao K, Chu L et al. Aurora kinases: novel therapy targets in cancers. *Oncotarget* 2017; 8(14): 23937–23954. doi: 10.18632/oncotarget.14893.

34. Li H, Zhang J, Lee MJ et al. *OIP5*, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and b-catenin signaling pathways. *Oncotarget* 2017; 8(11): 18129–18144. doi: 10.18632/oncotarget.15185.

35. Kumar V, Jagadish N, Suri A. Role of A-Kinase anchor protein (*AKAP4*) in growth and survival of ovarian cancer cells. *Oncotarget* 2017; 8(32): 53124–53136. doi: 10.18632/oncotarget.18163.

36. Han J, Gao W, Su D et al. Silencing of A-Kinase anchor protein 4 (*AKAP4*) inhibits proliferation and progression of thyroid cancer. *Oncol Res* 2017; 25(6): 873–878. doi: 10.3727/096504016X14783701102564.

37. Mesic A, Rogar M, Hudler P et al. Association of the *AURKA* and *AURKC* gene polymorphisms with an increased risk of gastric cancer. *IUBMB Life* 2016; 68(8): 634–644. doi: 10.1002/iub.1521.